Table 1 Sociodemographic and clinical characteristics of patients at baseline (prior treatment) and treatments at follow-up
Total | APOE4− | APOE4+ | p value | |
|---|---|---|---|---|
n = 334 | n = 270 | n = 64 | ||
Age, mean ± SD | 53.9 ± 11 | 54.3 ± 11 | 52.1 ± 10 | 0.13 |
Years 65+, n (%) | 53 (16) | 44 (16) | 9 (14) | |
Years 70+, n (%) | 21 (6) | 17 (6) | 4 (6) | |
Years of school, mean ± SD | 13.3 ± 2.7 | 13.2 ± 2.6 | 13.8 ± 3.1 | 0.17 |
Smoking status, n (%) | 0.46 | |||
Ever | 182 (54) | 144 (53) | 38 (59) | |
Never | 152 (46) | 126 (47) | 26 (41) | |
Menopausal status, n (%) | 0.25 | |||
Pre | 173 (52) | 135 (50) | 38 (59) | |
Post | 159 (48) | 133 (50) | 26 (41) | |
Missing | 2 (< 1) | 2 (< 1) | 0 (0) | |
Cancer stage, n (%) | 0.8 | |||
Stage I | 149 (45) | 120 (45) | 29 (45) | |
Stage II | 144 (43) | 115 (43) | 29 (45) | |
Stage III | 39 (12) | 33 (12) | 6 (10) | |
Missing | 2 (< 1) | 2 (< 1) | 0 (0) | |
Radiation therapy, n (%) | 312 (93) | 250 (93) | 62 (97) | 0.34 |
Chemotherapy, n (%) | 203 (61) | 167 (62) | 36 (56) | 0.49 |
Endocrine therapy, n (%) | 279 (84) | 227 (84) | 52 (81) | 0.72 |